[go: up one dir, main page]

MX2022010868A - Cepas bacterianas, las composiciones de las mismas y uso de las mismas en un procedimiento para el tratamiento de la deficiencia de vitamina d, y trastornos asociados a la misma. - Google Patents

Cepas bacterianas, las composiciones de las mismas y uso de las mismas en un procedimiento para el tratamiento de la deficiencia de vitamina d, y trastornos asociados a la misma.

Info

Publication number
MX2022010868A
MX2022010868A MX2022010868A MX2022010868A MX2022010868A MX 2022010868 A MX2022010868 A MX 2022010868A MX 2022010868 A MX2022010868 A MX 2022010868A MX 2022010868 A MX2022010868 A MX 2022010868A MX 2022010868 A MX2022010868 A MX 2022010868A
Authority
MX
Mexico
Prior art keywords
vitamin
deficiency
treatment
bacterial strains
disorders associated
Prior art date
Application number
MX2022010868A
Other languages
English (en)
Inventor
Walter Fiore
Andrea Biffi
Original Assignee
Sofar Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sofar Spa filed Critical Sofar Spa
Publication of MX2022010868A publication Critical patent/MX2022010868A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a cepas bacterianas para su uso en el tratamiento de una deficiencia y/o una insuficiencia de vitamina D y/o de enfermedades, síntomas y/o trastornos asociados a la misma. Es más, la presente invención se refiere a composiciones que comprenden al menos una de dichas cepas bacterianas y al menos una vitamina D, preferentemente vitamina D3, y al uso de las mismas en el tratamiento de dicha deficiencia y/o dicha insuficiencia de vitamina D y/o de enfermedades, síntomas o trastornos asociados a la misma.
MX2022010868A 2020-03-26 2021-04-28 Cepas bacterianas, las composiciones de las mismas y uso de las mismas en un procedimiento para el tratamiento de la deficiencia de vitamina d, y trastornos asociados a la misma. MX2022010868A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102020000006448A IT202000006448A1 (it) 2020-03-26 2020-03-26 Ceppi di batteri, loro composizioni e loro uso in un metodo per il trattamento di una carenza di vitamina d,e di disturbi associati
PCT/IB2021/052523 WO2021191855A1 (en) 2020-03-26 2021-04-28 Bacterial strains, the compositions thereof and use thereof in a method for the treatment of vitamin d deficiency, and disorders associated therewith

Publications (1)

Publication Number Publication Date
MX2022010868A true MX2022010868A (es) 2023-03-01

Family

ID=70978391

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010868A MX2022010868A (es) 2020-03-26 2021-04-28 Cepas bacterianas, las composiciones de las mismas y uso de las mismas en un procedimiento para el tratamiento de la deficiencia de vitamina d, y trastornos asociados a la misma.

Country Status (11)

Country Link
US (1) US12472214B2 (es)
EP (1) EP4125971A1 (es)
JP (1) JP2023519260A (es)
CN (1) CN115734788A (es)
AU (1) AU2021243859A1 (es)
BR (1) BR112022016240A2 (es)
CA (1) CA3175078A1 (es)
IL (1) IL295530A (es)
IT (1) IT202000006448A1 (es)
MX (1) MX2022010868A (es)
WO (1) WO2021191855A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113698503B (zh) * 2021-08-16 2022-05-24 华南理工大学 一种植物乳杆菌中性胞外多糖及其应用
CN116173077B (zh) * 2023-03-21 2025-07-25 哈尔滨医科大学 动物双歧杆菌的应用
CN116904378B (zh) * 2023-09-14 2023-12-29 山东中科嘉亿生物工程有限公司 促进骨成长的约氏乳杆菌jylo-010及菌剂、应用
WO2025110671A1 (ko) * 2023-11-20 2025-05-30 전북대학교산학협력단 지구력 증진 활성을 가지는 신균주
US12268717B1 (en) 2024-03-01 2025-04-08 Malireddy S. Reddy Enhanced microbial therapeutic agents
CN118806879A (zh) * 2024-09-19 2024-10-22 云南省药物研究所 一种具有骨关节保健作用的组合物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4486501A (en) 2000-03-27 2001-10-08 Pharming Intellectual Property Bv High dosage parenteral administration of lactoferrin
WO2006047744A2 (en) 2004-10-26 2006-05-04 Agennix Incorporated Compositions of lactoferrin related peptides and uses thereof
RU2010132283A (ru) 2008-02-06 2012-03-20 Дзе Проктер Энд Гэмбл Компани (US) Композиции, способы и наборы для повышения иммунного ответа на респираторное заболевание
IT1392672B1 (it) 2009-01-12 2012-03-16 Wyeth Consumer Healthcare S P A Composizioni comprendenti componenti probiotici e prebiotici e sali minerali, con lactoferrina
EP2455093A1 (en) 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic bacteria and prevention or treatment of infections in children
KR101235561B1 (ko) 2010-12-09 2013-03-21 주식회사 제일바이오 항바이러스 및 항균 활성을 갖는 락토바실러스 플란타룸 ｃｌｐ-1 균주 및 이를 포함하는 생균제
CN112195128B (zh) 2014-08-29 2023-05-02 科.汉森有限公司 益生菌青春双歧杆菌菌株
US12447200B2 (en) 2016-02-25 2025-10-21 Applied Biological Laboratories, Inc. Compositions and methods for protecting against airborne pathogens and irritants
WO2019089878A1 (en) 2017-11-02 2019-05-09 Colorado Seminary, Owner and Operator of University of Denver Methods of treating microbial infection and inflammation
AU2019289515B2 (en) * 2018-06-18 2025-07-24 Probi Ab Probiotic compositions and uses thereof
US20230098743A1 (en) * 2020-03-09 2023-03-30 Sofar S.P.A. Bacterial strains and compositions thereof for oral use in the treatment of viral infections of the respiratory system

Also Published As

Publication number Publication date
IL295530A (en) 2022-10-01
JP2023519260A (ja) 2023-05-10
AU2021243859A1 (en) 2022-09-08
WO2021191855A1 (en) 2021-09-30
EP4125971A1 (en) 2023-02-08
IT202000006448A1 (it) 2021-09-26
CA3175078A1 (en) 2021-09-30
US12472214B2 (en) 2025-11-18
BR112022016240A2 (pt) 2022-10-11
CN115734788A (zh) 2023-03-03
US20230190833A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
MX2022010868A (es) Cepas bacterianas, las composiciones de las mismas y uso de las mismas en un procedimiento para el tratamiento de la deficiencia de vitamina d, y trastornos asociados a la misma.
MA42376A (fr) Dérivés d'oxopyridine substitués
WO2019099682A9 (en) Compositions and methods for treating immune disorders using immune modulating lactococcus bacteria strains
MX2023010750A (es) Nuevos usos de derivados de piperidinil-indol.
AU2018326705A1 (en) Methods and compositions for treatment of microbiome-associated disorders
AR106800A1 (es) Composiciones que comprenden cepas bacterianas
GB201318761D0 (en) Compounds for the treatment of neuropsychiatric disorders
MA55434A (fr) Compositions comprenant des souches bactériennes
MY156777A (en) Substituted 2-acetamido-5-ary1-1,2,4-triazolones and use thereof
AU2016255707A8 (en) Uses of cannabidiol for treatment of infantile spasms
IL250832B (en) A mixture of beta-glycosylceramide and beta-lactosylceramide for use in the treatment of colitis
MX2016006708A (es) Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
MX2015009991A (es) Composiciones y metodos.
WO2022031847A3 (en) Compositions and methods for inhibiting plp1 expression
IN2012DN00624A (es)
MX2020013115A (es) Compuestos de tetrahidrobenzofuro[2,3-c]piridina y beta-carbolina para el tratamiento, el alivio o la prevencion de trastornos asociados con los agregados de tau.
WO2016036232A3 (en) Eurycoma longifolia extract and its use in enhancing and/or stimulating immune system
MY150931A (en) Substituted oxazolidinones and their use
FI20136184A7 (fi) Menetelmä maidon käsittelemiseksi
MX2023005591A (es) Metodos de tratamiento de enfermedades y trastornos.
ZA202002103B (en) Compounds as mpges-1 inhibitors
WO2023092141A3 (en) Compositions for metabolic health
ZA202211253B (en) Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases
MX2017007969A (es) Bacterias de acido lactico y su uso para el tratamiento de mastitis.
WO2019054641A3 (ko) 락토바실러스 플란타룸을 포함하는 위장관 질환의 예방 및 개선용 조성물